Maricopa Integrated Health Systems
Formulary Prior Auth Criteria

Drug: Leukine (Sargramostim)

Therapy:
A) Following induction chemotherapy in Acute Myelogenous Leukemia (AML).
   Is indicated for use following induction chemotherapy in older adult patients with AML to shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death. The safety and efficacy of Leukine have not bee assessed in patients with AML under 55 years old.
B) Use in myeloid reconstitution after Autologous/Allogeneic Bone Marrow Transplantation
   Is indicated for acceleration of myeloid recovery in patients with non-Hopkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL), and Hodgkin's disease undergoing autologous bone marrow transplantation (BMT).
   Is indicated for acceleration of myeloid recovery in patients undergoing allogenic BMT from HLA-matched related donors.
C) Use in bone marrow transplantation failure or engraftment delay
   Is indicated in patients who have undergone allogeneic or autologous (BMT) in whom engraftment is delayed or has failed. Survival benefit may be relatively greater in those patients who demonstrate one or more of the following characteristics: autologous BMT failure or engraftment delay, no previous total body irradiation, malignancy other than leukemia or a multiple organ failure (MOF) score less than or equal to 2.

Inclusions:
A) Lab work- complete CBC with differential
B) Diagnosis
C) Request comes from an Oncologist

Risk Factors/Contraindications:
In patients with excessive leukemic myeloid blasts in the bone marrow or peripheral blood (greater than or equal to 10%)
In patients with known hypersensitivity to GM-CSF yeast-derived products or any component of the product
For concomitant use with chemotherapy or radiotherapy
Drugs which may potentiate the myeloproliferative effects of Leukine, such as lithium and corticosteroids, should be used with caution

Authorization:
Two months

Medical Director_____
Date_____